Type of therapy | Target | Phase | Clinical trial number |
CAR T | EGFR | I | NCT03618381 |
CAR T | B7H3; CD19 | I | NCT04483778 |
CAR T | HER2 | I | NCT03740256 |
CAR T | HER2 | I | NCT04660929 |
CAR T | Glypican 3 | I | NCT02932956 |
CAR T | PSCA | I/II | NCT02744287 |
CAR T | ROR1 | I | NCT02706392 |
CAR T | Mesothelin | I | NCT03054298 |
CAR T | TnMUC1 | I | NCT04025216 |
TIL | Melanoma; HNSCC | I | NCT03991741 |
TIL | Melanoma; HNSCC; NSCLC | II | NCT03645928 |
TIL | Ovarian cancer; pancreatic ductal adenocarcinoma; colorectal cancer | II | NCT03610490 |
TIL | Ovarian cancer; anaplastic thyroid cancer; osteosarcoma | II | NCT03449108 |
TIL | Sarcoma | I | NCT04052334 |
TIL | Cervical cancer | II | NCT03108495 |
TIL | Various solid tumor cancers | II | NCT03935893 |
TCR | MAGE A4/8 | I | NCT03247309 |
TCR | Various solid tumor cancers—neoantigen TCRs | I | NCT03970382 |
TCR | Preferentially expressed antigen in melanoma-positive tumors | I | NCT03686124 |
TCR | MAGE A3/A6 | I | NCT03139370 |
TCR | HPV16+ cancers | I | NCT03912831 |
TCR | MAGE A4+ HNSCC | I | NCT04408898 |
TCR | NY-ESO-1 | I/II | NCT02650986 |
CAR, chimeric antigen receptor; EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; PSCA, prostate stem cell antigen; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte.